Research progress of Epstein-Barr virus determination and its clinical application

doi:10.3969/j.issn.1673-8640.2018.03.016

Abstract

Abstract:

Diseases caused by Epstein-Barr virus （EBV） infection are increasing,such as organ transplantation-associated EBV infection. Epithelial cell source tumor is correlated with EBV infection,and it is characterized by recessive infection and is often ignored in clinic. With the development of determination methods for EBV infection,especially quantitative determination of EBV DNA,combined with the results of immunological determination,pathogens could be timely determined in early infection period. It is potential for the dynamic monitoring and prognosis evaluation of EBV-related tumors. This review focuses on the determination methods of EBV from home and abroad and the relationship between EBV-related determination and tumors.

Key words: Epstein-Barr virus, Determination method, Tumor, Therapy

CLC Number:

R446.5

ZHANG Xu. Research progress of Epstein-Barr virus determination and its clinical application[J]. Laboratory Medicine, 2018, 33(3): 259-263.

References 35

1	BHADURI-MCLNTOSH S, LANDRY M L, NIKIFOROW S, et al. Serum IgA antibodies to Epstein-Barr virus (EBV) early lytic antigens are present in primary EBV infection[J]. J Infect Dis, 2007, 195(4):483-492.
2	卢璐, 孙文文, 袁风菊, 等. EB病毒在不同类型淋巴瘤中的表达及检测方法的比较[J]. 医学研究杂志, 2014, 43(2):80-83.
3	TAN E L, LOOI L M, SAM C K, et al. Evaluation of plasma Epstein-barr virus DNA load as a prognostic marker for nasopharyngeal carcinoma[J]. Singapore Med J, 2006, 47(9):803-807.
4	MEERBACH A, WUTZLER P, HÄFER R, et al. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease[J]. J Med Virol, 2008, 80(3):441-454.
5	BALFOUR H H Jr, HOKANSON K M, SCHACHERER R M, et al. A virologic pilot study of valacyclovir in infectious mononucleosis[J]. J Clin Virol, 2007, 39(1):16-21.
6	史会萍, 李榕, 段开文, 等. 云南省部分HIV感染者唾液EBV检出率分析[J]. 昆明医学院学报, 2012, 33(6):144-146.
7	孙文文, 万丽, 王群姬,等. 171例淋巴瘤病变组织中EB病毒表达情况的分析[J]. 癌变·畸变·突变, 2012, 24(1):60-63.
8	陆海英, 魏秀琴, 徐小元, 等. EBV抗体与EBV DNA 水平的影响因素及其相关性分析[J]. 临床肝胆病杂志, 2015, 31(5):766-770.
9	LI Y, WANG K, YIN S K, et al. Expression of Epstein-Barr virus antibodies EA-IgG, Rta-IgG, and VCA-IgA in nasopharyngeal carcinoma and their use in a combined diagnostic assay[J]. Genet Mol Res, 2016, 15(1).
10	朱超纲, 赵淑芬, 陈新林, 等. EB病毒DNA定量测定与鼻咽癌“中国2008TNM分期”的关系[J]. 中国肿瘤, 2011, 20(10): 772-774.
11	LEUNG S F, ZEE B, MA B B, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma[J]. J Clin Oncol, 2006, 24(34):5414-5418.
12	PENG H, CHEN L, ZHANG Y, et al. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status[J]. Oncotarget, 2016,7(17): 24208-24216.
13	WANG W Y, TWU C W, CHEN H H, et al. Plasma EBV DNA clearance rate as novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma[J]. Clin Cancer Res, 2010, 16(3):1016-1024.
14	RUIZ-BILBAO S, HERNANDEZ A, GOMEZ-SANCHEZ S, et al. AIDS-related primary CNS non-Hodgkin's lymphoma in a patient with previous Epstein-Barr virus panuveitis. A clinico-pathological report[J]. Arch Soc Esp Oftalmol, 2015, 90(50): 241-243.
15	MOORMANN A M, SNIDER C J, CHELIMO K. The company malaria keeps:how co-infection with Epstein-Barr virus leads to endemic Burkitt lymphoma[J]. Curr Opin Infect Dis, 201l, 24(5):435-441.
16	林云, 杨文萍, 黄慧, 等. EB病毒感染相关的儿童散发性伯基特淋巴瘤中miR-127和miR-155表达及意义[J]. 临床与实验病理学杂志, 2013, 29(10): 1076-1080.
17	SHIMATANI Y, NAKANO Y, TSUYAMA N, et al. Extranodal NK/T-cell lymphoma, nasal type, manifesting as rapidly progressive dementia without any mass or enhancing brain lesion[J]. Neuropathology, 2016,36(5): 456-463.
18	ABADI R Z, SISTANI N S, MOHTASHAM N, et al. The prevalence of Epstein-Barr virus infection in head and neck non-Hodgkin's lymphomas in Khorasan, northeast of Iran[J]. J Park Med Assoc, 2013,63(7):882-887.
19	MORISHIMA S, NAKAMURA S, YAMAMOTO K, et al. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma[J]. Leuk Lymphoma, 2015, 56(4):1072-1078.
20	HJALGRIM H, ASKLING J, ROSTGAARD K, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis[J]. N Engl J Med, 2003, 349(14):1324-1332.
21	DINAND V, SACHDEVA A, DATTA S, et al. Plasma Epstein Barr virus(EBV) DNA as a biomarker for EBV associated Hodgkin Lymphoma[J]. Indian Pediatr, 2015, 52(8): 681-685.
22	KANAKRY J A, LI H, GELLERT L L, et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial[J]. Blood, 2013, 121(18): 3547-3553.
23	CHIEREGHIN A, BERTUZZI C, PICCIRILLI G, et al. Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment[J]. Transpl Immunol, 2015, 34:60-64.
24	WEINTRAUB L, WEINER C, MILOH T, et al. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia[J]. J Pediatr Hematol Oncol, 2014,36(8):e481-e486.
25	韦华军, 杨长福, 钟亮, 等. EBV相关性胃癌患者血浆miRNAs 表达谱的研究[J]. 胃肠病学和肝病学杂志, 2014, 23(8): 885-888.
26	张钰, 吴梅青, 宣丽, 等. 脑脊液病毒载荷对评估基因HSCT后EB病毒相关性中枢神经系统疾病的临床意义[J]. 中华器官移植杂志, 2013, 34(2):92-96.
27	YUI S, YAMAGUCHI H, IMADOME K, et al. Epstein-Barr virus-positive T-cell lymphoproliferative disease following umbilical cord blood transplantation for acute myeloid leukemia[J]. J Nippon Med Sch, 2016, 83(1):35-42.
28	陈锟, 樊妮. 成人EB病毒相关噬血细胞综合征继发骨髓坏死1例及文献复习[J]. 检验医学, 2016, 31(10):925-928.
29	PURGINA B, RAO U N, MIETTINEN M, et al. AIDS-related EBV-associated smooth muscle tumors: a review of 64 published cases[J]. Patholog Res Int, 2011,2011:561548.
30	SUWAN Y, ROJANAPORN D, TEEKHASAENEE C, et al. Epstein-Barr virus-associated iris smooth muscle tumor with epithelioid morphology in AIDS patients: a case report[J]. Int Med Case Rep J, 2016,9:83-86.
31	GHOSH S K, PERRINE S P, FALLER D V. Advances in virus-directed therapeutics against Epstein-Barr virus-associated malignancies[J]. Adv Virol, 2012:509296.
32	KENNEY S C, FINGEROTH J D. Molecular basis for therapy of AIDS-defining cancers[M].New York:Springer-Verlag,2010:111-135.
33	GHOSH S K, FORMAN L W, AKINSHEYE I, et al. Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents[J]. Blood Cells Mol Dis, 2007, 38(1):57-65.
34	BALAMUTH N J, NICHOLS K E, PAESSLER M, et al. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis[J]. J Pediatr Hematol Oncol, 2007, 29(8):569-573.
35	WORTH A, CONYERS R, COHEN J, et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation[J]. Br J Haematol, 2011, 155(3):377-385.

[1]	ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811.
[2]	PENG Wei, LI Yungai, XU Jing, LIU Hua, YANG Cuixia, SHEN Yunyue. Serum inflammatory factors combined with PSA and f-PSA in the auxiliary diagnosis of prostate cancer [J]. Laboratory Medicine, 2023, 38(9): 849-854.
[3]	DING Xiaoyuan, DAI Jinsheng, JIAO Ronghong, MA Suli, ZHU Haifeng, WU Mengya, CHE Yanran, ZHANG Lei. Influence of obesity/overweight on inflammatory factors of Th1/Th2 and Th17/Treg in children with asthma attacks [J]. Laboratory Medicine, 2023, 38(8): 748-752.
[4]	ZHANG Na, NIU Weihua, SUN Yuanyuan, JIA Mei. CMV and EBV co-infection affecting patient prognosis after hematopoietic stem cell transplantation [J]. Laboratory Medicine, 2023, 38(8): 760-765.
[5]	ZHAO Jing, WANG Pei, LU Dandan, QI Dandan, LI Xuan. Expression levels of serum miR-4443 and TRAF4 in patients with hemorrhagic stroke [J]. Laboratory Medicine, 2023, 38(5): 413-418.
[6]	YU Qi, WANG Yanchun, GUO Lin, LU Renquan. Influence of particle radiotherapy on bone marrow，liver and kidney functions in patients with prostate cancer [J]. Laboratory Medicine, 2023, 38(5): 430-434.
[7]	GAO Feng. Clinical application of novel tumor biomarkers：prospects and challenges [J]. Laboratory Medicine, 2023, 38(4): 303-306.
[8]	YUAN Shuang, FENG Lei, GUO Xiaofen, FU Xiaoling, XU Jing, LIU Hongyang. Relation of miR-433 in endometrial cancer tissues and its relationship with chemotherapy sensitivity [J]. Laboratory Medicine, 2023, 38(4): 337-341.
[9]	SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis [J]. Laboratory Medicine, 2023, 38(4): 347-351.
[10]	CHEN Zhe, ZHANG Ling, LIU Jie, WANG Xia, ZHANG Bin, GAO Binghua. Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy [J]. Laboratory Medicine, 2023, 38(3): 251-256.
[11]	WU Jiong, HU Jiahua, SHI Meifang, LIU Tao, DAI Jie, LU Xinyi, ZOU Zheng. Research progress of biomarkers of prostate cancer [J]. Laboratory Medicine, 2023, 38(2): 190-195.
[12]	GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206，miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068.
[13]	QIAN Linyu, LIANG Weifang, TANG Sichen. Determination and clinical significance of NLRP3，CTRP6 and IL-1β in patients with gestational diabetes mellitus [J]. Laboratory Medicine, 2023, 38(10): 936-940.
[14]	GUO Shuang, LIU Hongli, LI Ya. Progression of migration and invasion-related miRNA and lncRNA in Epstein-Barr virus-associated gastric cancer [J]. Laboratory Medicine, 2023, 38(10): 987-996.
[15]	WU Yating, LI Zhuolin, LEI Yan, JIA Ruxue, ZHANG Shenghang, WANG Shuiliang. Research progress of miRNA in urine as a biomarker for common malignant tumors [J]. Laboratory Medicine, 2023, 38(1): 94-99.